ArticleAging cell2013
Reducing sphingolipid synthesis orchestrates global changes to extend yeast lifespan.
Article in Aging cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 74 citations in OpenAlex.
- Proteome Responses to Acute Inhibition of De Novo Sphingolipid Synthesis Suggest Cancer Combination Therapies.Cancers · 2026Article
- Sphingolipid and methionine metabolism in aging.Journal of cell science · 2025Review
- The Trade-Off Between the Increased Colony Nurturing Ability and the Decreased Lifespan of Worker Bees (Insects · 2025Article
- Do circulating sphingolipid species correlate with age? A study in a normoglycemic biracial population.Biogerontology · 2025Article
- Article
- Accumulation of Damaging Lipids in the Arf1-Ablated Neurons Promotes Neurodegeneration through Releasing mtDNA and Activating Inflammatory Pathways in Microglia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Sugar accelerates chronological aging in yeast via ceramides.Cell stress · 2025Review
- Transposon-sequencing (Tn-seq) of the Candida glabrata reference strain CBS138 reveals epigenetic plasticity, structural variation, and intrinsic mechanisms of resistance to micafungin.G3 (Bethesda, Md.) · 2024Article
- Article
- Pharmacological inhibition of sphingolipid synthesis reduces ferroptosis by stimulating the HIF-1 pathway.iScience · 2022Article
- Long-lived Humans Have a Unique Plasma Sphingolipidome.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Pleiotropic effects of mitochondria in aging.Nature aging · 2022Review
- Extension of chronological lifespan in Schizosaccharomyces pombe.Genes to cells : devoted to molecular & cellular mechanisms · 2021Review
- Aging-dependent mitochondrial dysfunction mediated by ceramide signaling inhibits antitumor T cell response.Cell reports · 2021Article
- Article
- Implications of Sphingolipids on Aging and Age-Related Diseases.Frontiers in aging · 2021Review
- Sphinganine-Analog Mycotoxins (SAMs): Chemical Structures, Bioactivities, and Genetic Controls.Journal of fungi (Basel, Switzerland) · 2020Review
- The Lipidome Fingerprint of Longevity.Molecules (Basel, Switzerland) · 2020Review
- Structural insights into telomere protection and homeostasis regulation by yeast CST complex.Nature structural & molecular biology · 2020Article
- Insights into the Conserved Regulatory Mechanisms of Human and Yeast Aging.Biomolecules · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Studies of aging and longevity are revealing how diseases that shorten life can be controlled to improve the quality of life and lifespan itself. Two strategies under intense study to accomplish these goals are rapamycin treatment and calorie restriction. New strategies are being discovered including one that uses low-dose myriocin treatment. Myriocin inhibits the first enzyme in sphingolipid synthesis in all eukaryotes, and we showed recently that low-dose myriocin treatment increases yeast lifespan at least in part by down-regulating the sphingolipid-controlled Pkh1/2-Sch9 (ortholog of mammalian S6 kinase) signaling pathway. Here we show that myriocin treatment induces global effects and changes expression of approximately forty percent of the yeast genome with 1252 genes up-regulated and 1497 down-regulated (P < 0.05) compared with untreated cells. These changes are due to modulation of evolutionarily conserved signaling pathways including activation of the Snf1/AMPK pathway and down-regulation of the protein kinase A (PKA) and target of rapamycin complex 1 (TORC1) pathways. Many processes that enhance lifespan are regulated by these pathways in response to myriocin treatment including respiration, carbon metabolism, stress resistance, protein synthesis, and autophagy. These extensive effects of myriocin match those of rapamycin and calorie restriction. Our studies in yeast together with other studies in mammals reveal the potential of myriocin or related compounds to lower the incidence of age-related diseases in humans and improve health span.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.